ALK-Abelló A/S (AKBLF)
USD 21.35
(-4.47%)
USD 21.35
(-4.47%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.72 Billion DKK | 6.63% |
| 2022 | 6.3 Billion DKK | 8.2% |
| 2021 | 5.83 Billion DKK | 4.8% |
| 2020 | 5.56 Billion DKK | 1.24% |
| 2019 | 5.49 Billion DKK | 12.95% |
| 2018 | 4.86 Billion DKK | -1.88% |
| 2017 | 4.95 Billion DKK | 3.31% |
| 2016 | 4.79 Billion DKK | 12.86% |
| 2015 | 4.25 Billion DKK | 24.36% |
| 2014 | 3.41 Billion DKK | 4.62% |
| 2013 | 3.26 Billion DKK | -0.43% |
| 2012 | 3.28 Billion DKK | -2.15% |
| 2011 | 3.35 Billion DKK | 18.52% |
| 2010 | 2.83 Billion DKK | 6.67% |
| 2009 | 2.65 Billion DKK | 4.53% |
| 2008 | 2.53 Billion DKK | -10.03% |
| 2007 | 2.82 Billion DKK | 1.15% |
| 2006 | 2.78 Billion DKK | -59.67% |
| 2005 | 6.91 Billion DKK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 6.78 Billion DKK | 0.86% |
| 2024 Q2 | 7.04 Billion DKK | 3.85% |
| 2023 Q3 | 6.56 Billion DKK | 1.72% |
| 2023 Q1 | 6.35 Billion DKK | 0.76% |
| 2023 FY | 6.72 Billion DKK | 6.63% |
| 2023 Q4 | 6.72 Billion DKK | 2.41% |
| 2023 Q2 | 6.45 Billion DKK | 1.59% |
| 2022 Q3 | 6.28 Billion DKK | 1.21% |
| 2022 Q2 | 6.2 Billion DKK | 4.02% |
| 2022 Q1 | 5.96 Billion DKK | 2.35% |
| 2022 FY | 6.3 Billion DKK | 8.2% |
| 2022 Q4 | 6.3 Billion DKK | 0.41% |
| 2021 Q3 | 5.71 Billion DKK | 2.57% |
| 2021 Q4 | 5.83 Billion DKK | 1.96% |
| 2021 FY | 5.83 Billion DKK | 4.8% |
| 2021 Q1 | 5.78 Billion DKK | 3.99% |
| 2021 Q2 | 5.57 Billion DKK | -3.63% |
| 2020 FY | 5.56 Billion DKK | 1.24% |
| 2020 Q1 | 5.63 Billion DKK | 2.62% |
| 2020 Q2 | 5.68 Billion DKK | 0.78% |
| 2020 Q3 | 5.57 Billion DKK | -1.94% |
| 2020 Q4 | 5.56 Billion DKK | -0.18% |
| 2019 Q3 | 5.09 Billion DKK | -0.57% |
| 2019 Q2 | 5.12 Billion DKK | -2.16% |
| 2019 Q4 | 5.49 Billion DKK | 7.94% |
| 2019 Q1 | 5.23 Billion DKK | 7.56% |
| 2019 FY | 5.49 Billion DKK | 12.95% |
| 2018 Q2 | 4.94 Billion DKK | 0.47% |
| 2018 FY | 4.86 Billion DKK | -1.88% |
| 2018 Q3 | 4.86 Billion DKK | -1.7% |
| 2018 Q4 | 4.86 Billion DKK | 0.08% |
| 2018 Q1 | 4.92 Billion DKK | -0.73% |
| 2017 FY | 4.95 Billion DKK | 3.31% |
| 2017 Q3 | 4.5 Billion DKK | -1.83% |
| 2017 Q1 | 4.82 Billion DKK | 0.5% |
| 2017 Q4 | 4.95 Billion DKK | 10.18% |
| 2017 Q2 | 4.58 Billion DKK | -4.96% |
| 2016 Q2 | 4.5 Billion DKK | 1.81% |
| 2016 FY | 4.79 Billion DKK | 12.86% |
| 2016 Q3 | 4.52 Billion DKK | 0.49% |
| 2016 Q4 | 4.79 Billion DKK | 6.06% |
| 2016 Q1 | 4.42 Billion DKK | 4.02% |
| 2015 Q4 | 4.25 Billion DKK | 5.93% |
| 2015 Q1 | 3.58 Billion DKK | 4.74% |
| 2015 Q2 | 3.9 Billion DKK | 9.16% |
| 2015 Q3 | 4.01 Billion DKK | 2.69% |
| 2015 FY | 4.25 Billion DKK | 24.36% |
| 2014 Q1 | 3.34 Billion DKK | 2.36% |
| 2014 Q2 | 3.31 Billion DKK | -0.81% |
| 2014 Q3 | 3.36 Billion DKK | 1.39% |
| 2014 Q4 | 3.41 Billion DKK | 1.63% |
| 2014 FY | 3.41 Billion DKK | 4.62% |
| 2013 Q2 | 3.22 Billion DKK | -1.83% |
| 2013 FY | 3.26 Billion DKK | -0.43% |
| 2013 Q4 | 3.26 Billion DKK | 1.55% |
| 2013 Q3 | 3.21 Billion DKK | -0.12% |
| 2013 Q1 | 3.28 Billion DKK | 0.0% |
| 2012 Q4 | 3.28 Billion DKK | 0.34% |
| 2012 FY | 3.28 Billion DKK | -2.15% |
| 2012 Q1 | 3.34 Billion DKK | -0.33% |
| 2012 Q2 | 3.2 Billion DKK | -4.07% |
| 2012 Q3 | 3.27 Billion DKK | 2.0% |
| 2011 Q4 | 3.35 Billion DKK | 11.91% |
| 2011 Q1 | 3.05 Billion DKK | 8.02% |
| 2011 Q2 | 2.94 Billion DKK | -3.66% |
| 2011 Q3 | 2.99 Billion DKK | 1.77% |
| 2011 FY | 3.35 Billion DKK | 18.52% |
| 2010 Q1 | 2.72 Billion DKK | 2.75% |
| 2010 FY | 2.83 Billion DKK | 6.67% |
| 2010 Q4 | 2.83 Billion DKK | 4.78% |
| 2010 Q3 | 2.7 Billion DKK | 0.78% |
| 2010 Q2 | 2.68 Billion DKK | -1.69% |
| 2009 Q4 | 2.65 Billion DKK | 0.0% |
| 2009 FY | 2.65 Billion DKK | 4.53% |
| 2008 FY | 2.53 Billion DKK | -10.03% |
| 2007 FY | 2.82 Billion DKK | 1.15% |
| 2006 FY | 2.78 Billion DKK | -59.67% |
| 2005 FY | 6.91 Billion DKK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -291168731.169% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -5065.472% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -872676.535% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1218113.432% |
| Qrons Inc. | 420.00 USD | -1601428471.429% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1901957.876% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -63629.392% |
| BioStem Technologies, Inc. | 14.56 Million USD | -46094.132% |
| Skye Bioscience, Inc. | 11.94 Million USD | -56229.719% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1399525.851% |
| Rebus Holdings, Inc. | 5000.00 USD | -134519900.0% |
| CSL Limited | 38.02 Billion USD | 82.31% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -23969.568% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -12662.566% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -978247.195% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -343380.634% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -17214.078% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -93060.966% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -8808868.751% |
| SQZ Biotechnologies Company | 107.18 Million USD | -6175.015% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -469582.242% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -9294448.47% |
| Mesoblast Limited | 667.9 Million USD | -907.036% |
| Marizyme, Inc. | 22.01 Million USD | -30451.792% |
| Genus plc | 1.02 Billion USD | -553.708% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -495058.475% |
| Pharming Group N.V. | 462.85 Million USD | -1353.158% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -202917.677% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1347690.453% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1072627.273% |
| ContraFect Corporation | 20.67 Million USD | -32425.751% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1722898.417% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -1759817.525% |
| IMV Inc. | 31.33 Million USD | -21365.647% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -162127.793% |
| MultiCell Technologies, Inc. | 126.22 USD | -5328790899.842% |
| ONE Bio Corp. | 70.08 Million USD | -9496.849% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -715668.728% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -5133.834% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1557875.882% |
| Q BioMed Inc. | 3.51 Million USD | -191223.211% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -19019.361% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -2574179.405% |
| Biomind Labs Inc. | 73.81 Thousand USD | -9111375.365% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -1407.028% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -464132.494% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -22308.831% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -244808.214% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -258274.706% |
| GB Sciences, Inc. | 103.44 Thousand USD | -6502094.466% |
| Alpha Cognition Inc. | 2.45 Million USD | -274187.672% |
| HST Global, Inc. | 1526.00 USD | -440760057.274% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -680691.97% |
| Halberd Corporation | 10.13 Thousand USD | -66390187.237% |
| Enzolytics Inc. | 361.7 Million USD | -1759.518% |
| Agentix Corp. | 261.39 Thousand USD | -2573046.845% |
| Resverlogix Corp. | 8.11 Million USD | -82783.549% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -358069.851% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | -48.07% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -14000.038% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1051402.683% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -29524503.837% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -75057.934% |
| AVAX Technologies, Inc. | 7.37 Million USD | -91073.334% |
| Zenith Capital Corp. | 7410.00 USD | -90769130.769% |
| Genscript Biotech Corporation | 3.38 Billion USD | -98.619% |
| Ember Therapeutics, Inc. | 184.00 USD | -3655434682.609% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2089979.116% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -2573322.507% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -724714.944% |
| Kadimastem Ltd | 2.3 Million USD | -291816.947% |
| Helix BioMedix, Inc. | 3.02 Million USD | -222240.786% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -11780472.389% |
| LadRx Corporation | 2.3 Million USD | -291336.044% |
| Cell Source, Inc. | 195.17 Thousand USD | -3446108.709% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1901957.876% |
| NovAccess Global Inc. | 62.24 Thousand USD | -10805066.431% |
| Affymax, Inc. | 7.44 Million USD | -90266.788% |
| Itoco Inc. | 1.4 Million USD | -480303.865% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -7031272.508% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -6345183.019% |
| Mobile Lads Corp. | 52.00 USD | -12934615284.615% |
| CytoDyn Inc. | 11.13 Million USD | -60298.707% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -4704317.648% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -37617349.664% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -1744778.344% |
| SYBLEU INC | 330.46 Thousand USD | -2035195.399% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1642703.757% |
| International Stem Cell Corporation | 5.39 Million USD | -124686.642% |
| Bioxytran, Inc. | 137.63 Thousand USD | -4886631.862% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -44734.53% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -40469.395% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -8513824.051% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -777762.716% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -89377.185% |
| Neutra Corp. | 2851.00 USD | -235917122.027% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -20655.416% |
| PureTech Health plc | 693.97 Million USD | -869.202% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -83234.479% |
| IXICO plc | 15.84 Million USD | -42351.661% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -81112.268% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -6409.62% |
| CSL Limited | 38.02 Billion USD | 82.31% |
| Cellectis S.A. | 333.99 Million USD | -1913.805% |